Weiran Wang
Research Subjects
Weiran Wang has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Bin Yu
National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin province, People's Republic of China
1 shared publicationBobo Li
Department of Thoracic Surgery Shandong Cancer Hospital Affiliated to Shandong University Jinan China
1 shared publicationChu Wang
National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin province, People's Republic of China
1 shared publicationDanhua Wang
Department of Translational Medicine Genetron Health (Beijing) Technology, Co. Ltd. Beijing China
1 shared publication- Dezhi Cheng
The First Affiliated Hospital of Wenzhou Medical University
1 shared publication Dongxiao Lv
Tumor Research and Therapy Center Shandong Provincial Hospital Affiliated to Shandong First Medical University Jinan China
1 shared publication
Latest Publications
- Open Access
- 28 October 2021
- Published by Wiley in Cancer Science
- Vol. 113 (1) , 308-318
Identification of RET fusions in a Chinese multicancer retrospective analysis by next‐generation sequencing
Fusion of RET with different partner genes has been detected in papillary thyroid, lung, colorectal, pancreatic, and breast cancer. Approval of selpercatinib for treatment of lung and thyroid cancer with RET gene mutations or fusions calls for studies to explore RET fusion partners and their eligibility for RET‐based targeted therapy. In this study, RET fusion patterns in a large group of Chinese cancer patients covering several cancer types were identified using next‑generation sequencing. A total of 44 fusion patterns were identified in the study cohort with KIF5B, CCDC6, and ERC1 being the most common RET fusion partners. Notably, 17 novel fusions were first reported in this study. Prevalence of functional RET fusions was 1.05% in lung cancer, 6.03% in thyroid cancer, 0.39% in colorectal cancer, and less than 0.1% in gastric cancer and hepatocellular carcinoma. Analysis showed a preference for fusion partners in different tumor types, with KIF5B being the common type in lung cancer, CCDC6 in thyroid cancer, and NCOA4 in colorectal cancer. Co‐occurrence of EGFR mutations and RET fusions with rare partner genes (rather than KIF5B) in lung cancer patients was correlated with epidermal growth factor receptor‐tyrosine kinase inhibitor resistance and could predict response to targeted therapies. Findings from this study provide a guide to clinicians in determining tumors with specific fusion patterns as candidates for RET targeted therapies.
- 28 October 2021
- Published by Wiley in Cancer Science
- Vol. 113 (1) , 308-318
Open AccessIdentification of RET fusions in a Chinese multicancer retrospective analysis by next‐generation sequencing
Fusion of RET with different partner genes has been detected in papillary thyroid, lung, colorectal, pancreatic, and breast cancer. Approval of selpercatinib for treatment of lung and thyroid cancer with RET gene mutations or fusions calls for studies to explore RET fusion partners and their eligibility for RET‐based targeted therapy. In this study, RET fusion patterns in a large group of Chinese cancer patients covering several cancer types were identified using next‑generation sequencing. A total of 44 fusion patterns were identified in the study cohort with KIF5B, CCDC6, and ERC1 being the most common RET fusion partners. Notably, 17 novel fusions were first reported in this study. Prevalence of functional RET fusions was 1.05% in lung cancer, 6.03% in thyroid cancer, 0.39% in colorectal cancer, and less than 0.1% in gastric cancer and hepatocellular carcinoma. Analysis showed a preference for fusion partners in different tumor types, with KIF5B being the common type in lung cancer, CCDC6 in thyroid cancer, and NCOA4 in colorectal cancer. Co‐occurrence of EGFR mutations and RET fusions with rare partner genes (rather than KIF5B) in lung cancer patients was correlated with epidermal growth factor receptor‐tyrosine kinase inhibitor resistance and could predict response to targeted therapies. Findings from this study provide a guide to clinicians in determining tumors with specific fusion patterns as candidates for RET targeted therapies.
- 1 November 2020
- Published by Elsevier in Protein Expression and Purification
- Vol. 175, 105688
Antibody development and property analysis of RhBST2 for accurate cell biological and viral research
- 1 November 2020
- Published by Elsevier in Protein Expression and Purification
- Vol. 175, 105688
Antibody development and property analysis of RhBST2 for accurate cell biological and viral research